Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 36 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.

• Investigation of Drug-drug Interaction of Nintedanib and Ketoconazole in Healthy Male VolunteersCompletedNCT01679613Phase 1Results posted
• BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract CancerTerminatedNCT01679405Phase 1Results posted
• Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal CancerCompletedNCT01676714Phase 2Results posted
• A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCCTerminatedNCT01673386Phase 2Results posted
• Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform NeurofibromasCompletedNCT01673009Phase 2Results posted
• A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple MyelomaTerminatedNCT01672736Phase 1/2Results posted
• Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast CancerCompletedNCT01670877Phase 2Results posted
• BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian CancerCompletedNCT01669798Phase 2Results posted
• A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT01667562Phase 3Results posted
• A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)CompletedNCT01667133Phase 1/2Results posted
• Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01664897Phase 2Results posted
• A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic CancerCompletedNCT01663272Phase 1Results posted
• Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid CarcinomaCompletedNCT01661179Phase 1/2Results posted
• Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to ImatinibCompletedNCT01660906Phase 4Results posted
• Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLLCompletedNCT01659255Phase 1Results posted
• An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver CancerCompletedNCT01658878Phase 1/2Results posted
• A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating MutationsCompletedNCT01657682Phase 2Results posted
• Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic AdenocarcinomaCompletedNCT01652976Phase 2Results posted
• Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.CompletedNCT01652469Phase 3Results posted
• Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)TerminatedNCT01650805Phase 3Results posted
• NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell CarcinomaTerminatedNCT01649180Phase 2Results posted
• Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior TherapyCompletedNCT01646021Phase 3Results posted
• A Long Term Study to Assess the Safety of Fostamatinib in Patients in Asia With Rheumatoid ArthritisTerminatedNCT01640054Phase 2Results posted
• A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer PatientsCompletedNCT01639001Phase 3Results posted
• A Study to Continue ASP015K Treatment to Rheumatoid Arthritis Patients Who Completed Phase IIb Study or Phase III Study of ASP015KCompletedNCT01638013Phase 3Results posted
• Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief StudyCompletedNCT01632904Phase 3Results posted
• Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate CancerCompletedNCT01630590Phase 2Results posted
• Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung CancerCompletedNCT01625234Phase 1/2Results posted
• Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast CancerCompletedNCT01622868Phase 2Results posted
• Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based ChemotherapyTerminatedNCT01622660Phase 2Results posted
• Sunitinib for Advanced Thymus Cancer Following Earlier TreatmentCompletedNCT01621568Phase 2Results posted
• Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous LeukemiaTerminatedNCT01620216Phase 2Results posted
• Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary FibrosisCompletedNCT01619085Phase 3Results posted
• Ibrutinib (PCI-32765) in Waldenstrom's MacroglobulinemiaCompletedNCT01614821Phase 2Results posted
• Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral SurgeryCompletedNCT01612351Phase 2Results posted
• Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or StomachCompletedNCT01611857Phase 1/2Results posted
• A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01611090Phase 3Results posted
• A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi TreatmentCompletedNCT01610336Phase 2Results posted
• A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian CancerCompletedNCT01610206Phase 2Results posted
• A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR MutationsCompletedNCT01609543Phase 4Results posted
• Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100CompletedNCT01605227Phase 3Results posted
• Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney CancerTerminatedNCT01599832Not applicableResults posted
• Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate CancerCompletedNCT01599793Phase 2Results posted
• Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk PatientsTerminatedNCT01599754Phase 3Results posted
• Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast CancerCompletedNCT01596751Phase 1/2Results posted
• Ruxolitinib in Estrogen Receptor Positive Breast CancerCompletedNCT01594216Phase 2Results posted
• A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue SarcomaCompletedNCT01593748Phase 2Results posted
• Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to ImatinibCompletedNCT01593254Phase 2Results posted
• Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal MesotheliomaCompletedNCT01592383Phase 2Results posted
• PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic LeukemiaActive, not recruitingNCT01589302Phase 2Results posted
• Cabozantinib in Advanced Solid MalignanciesCompletedNCT01588821Phase 2Results posted
• A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)CompletedNCT01586624Phase 1Results posted
• Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic CancerCompletedNCT01582191Phase 1Results posted
• Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric CancerTerminatedNCT01579578Phase 2Results posted
• A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedNCT01578707Phase 3Results posted
• Hepatic Impairment Study For Crizotinib In Advanced Cancer PatientsCompletedNCT01576406Phase 1Results posted
• Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After SurgeryActive, not recruitingNCT01575548Phase 3Results posted
• Tivantinib in Treating Patients With Recurrent or Metastatic Breast CancerCompletedNCT01575522Phase 2Results posted
• Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)CompletedNCT01573702Phase 2Results posted
• Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)TerminatedNCT01570868Phase 2Results posted
• Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid ArthritisTerminatedNCT01569074Phase 2Results posted
• Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01565668Phase 2Results posted
• Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung AdenocarcinomaCompletedNCT01565538Phase 2Results posted
• Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid ArthritisCompletedNCT01563978Phase 2Results posted
• Ruxolitinib in Patients With Breast CancerTerminatedNCT01562873Phase 2Results posted
• BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)CompletedNCT01562028Phase 2Results posted
• A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma PatientsCompletedNCT01561833Phase 1Results posted
• Linsitinib in Treating Patients With Gastrointestinal Stromal TumorsCompletedNCT01560260Phase 2Results posted
• A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT01559363Phase 1/2Results posted
• Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)CompletedNCT01558739Phase 4Results posted
• Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic CarcinomaCompletedNCT01558661Phase 2Results posted
• Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT01557959Phase 2Results posted
• A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy AloneCompletedNCT01544179Phase 3Results posted
• A Study of LY3009104 in Healthy ParticipantsCompletedNCT01536951Phase 1Results posted
• Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive GenotypeCompletedNCT01534260Phase 1/2Results posted
• Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by SurgeryTerminatedNCT01533948Phase 2Results posted
• Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate CancerCompletedNCT01533246Phase 2Results posted
• Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung CancerCompletedNCT01533181Phase 2Results posted
• Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue SarcomaCompletedNCT01532687Phase 2Results posted
• Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous TreatmentCompletedNCT01530334Phase 2Results posted
• A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different TreatmentsCompletedNCT01529112Phase 2Results posted
• Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast CancerTerminatedNCT01528345Phase 2Results posted
• Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) PatientsTerminatedNCT01526928Phase 1/2Results posted
• Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid TumorsCompletedNCT01525602Phase 1Results posted
• A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine TumorsCompletedNCT01525550Phase 4Results posted
• Study of Dovitinib (TKI258) in Adenoid Cystic CarcinomaCompletedNCT01524692Phase 2Results posted
• LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based ChemotherapyCompletedNCT01523587Phase 3Results posted
• Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With RuxolitinibTerminatedNCT01523171Phase 2Results posted
• Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric CancerCompletedNCT01522768Phase 2Results posted
• Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating MutationsCompletedNCT01522469Phase 2Results posted
• Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate CancerTerminatedNCT01522443Phase 3Results posted
• Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.CompletedNCT01520870Phase 2Results posted
• Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma PatientsCompletedNCT01520519Phase 2Results posted
• Tivantinib in Treating Patients With Metastatic Prostate CancerCompletedNCT01519414Phase 2Results posted
• A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic ArthritisCompletedNCT01519089Phase 3Results posted
• Phase II Study of Alternating Sunitinib and TemsirolimusCompletedNCT01517243Phase 2Results posted
• Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF MutationTerminatedNCT01514864Phase 2Results posted
• Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA)CompletedNCT01513902Phase 1Results posted
• Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric CancerCompletedNCT01512745Phase 3Results posted
• Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL)TerminatedNCT01510756Phase 2Results posted

← Tyrosine Kinase Inhibitors overview